Physician profile
David W Croy
NPI 1164499588
$567.08
in general payments reported to CMS, 2019-2025
19 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $57.71 · 2023: $130 · 2024: $219 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $65.92 | 2023-2025 | |
| Celgene Corporation | $59.35 | 2024-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $51.44 | 2023-2025 | Airsupra, Calquence |
| Merck Sharp & Dohme LLC | $47.47 | 2022-2025 | Keytruda |
| Janssen Biotech, INC. | $46.13 | 2022-2024 | Erleada |
| Jazz Pharmaceuticals INC. | $40.14 | 2023 | |
| Rigel Pharmaceuticals, INC. | $34.42 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Kyowa Kirin, INC. | $31.72 | 2023-2024 | Poteligeo |
| Adaptive Biotechnologies Corporation | $24.04 | 2024 | Clonoseq |
| Genzyme Corporation | $23.42 | 2022 | |
| Blueprint Medicines Corporation | $22.60 | 2023 | Ayvakit |
| Ferring Pharmaceuticals INC. | $19.77 | 2024 | Adstiladrin |
| Springworks Therapeutics, INC. | $19.26 | 2024 | Ogsiveo |
| Incyte Corporation | $18.83 | 2024 | Monjuvi, Pemazyre |
| Genmab U.S., INC. | $18.71 | 2025 | Tivdak |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2025 | Ninlaro |
| Pfizer INC. | $14.42 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Organon LLC | $2.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Croy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.